Extended reports
Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both)
Marja Pertovaaraa, Markku Korpelaa, Hannu Uusitalob, Juhani Pukanderc, Ari Miettinend, Heikki Heline, Amos Pasternackc
a Department of
Internal Medicine, Tampere University Hospital, Finland, b Department of
Ophthalmology, Tampere University Hospital, Finland, c Medical School, University of Tampere, Finland, d Clinical
Microbiology Unit, Tampere University Hospital, Finland, e Pathology Unit, Tampere University
Hospital, Finland
Correspondence to: Dr M Pertovaara, Department of Internal Medicine, Section of Rheumatology, Tampere University Hospital, PO Box 2000, FIN-33521 Tampere, Finland.
Accepted for publication 18 March 1999
| |
Abstract |
|---|
|
|
|---|
OBJECTIVE
To assess
the prognosis of patients with sicca symptoms and to identify the
clinical and immunological factors that most sensitively predict the
later development of primary Sjögren's syndrome (SS) or other
connective tissue diseases.
METHODS
Eighty seven
patients (72 female, 15 male) with sicca symptoms were re-evaluated
after a median follow up time of 11 years (range 8-17). The clinical
examination included ophthalmological examination (Schirmer's test,
break up time and Rose-Bengal staining). Labial salivary gland biopsy
was performed and histological findings graded according to the
Chisholm-Mason scale. The immunoserological tests included
determination of rheumatoid factor (RF), antinuclear antibodies (ANA),
anti-extractable nuclear antigen-antibodies (ENA), serum
immunoglobulins IgA, IgG, and IgM, and serum
2-microglobulin (
2m).
RESULTS
At follow up
31 patients (36%) fulfilled modified Californian criteria (salivary
flow measurements were not performed and Chisholm-Mason grades 3-4
were regarded as diagnostic histological findings) for possible or
definite SS. Likewise, a significant progression of the histological
findings was observed. Labial salivary gland re-biopsy was performed in
42 patients with grade 0-2 findings at baseline, progression to grades
3-4 being observed in 21 (50%) at follow up. The patients who later
developed SS were at baseline significantly older (mean (SD) 52 (9)
v 44 (14) years, p
0.005) compared with
those not fulfilling the SS criteria at follow up; they also had
significantly higher serum
2m (p
0.0005) and IgG
concentrations (p
0.005), and they had positive ANA more frequently
(p
0.01).
CONCLUSION
These
results suggest that high age, increased values of serum
2m, ANA positivity and increased concentrations of serum
IgG, might be useful indicators for the subsequent development of SS in
patients with sicca symptoms. The prognosis of patients with these
symptoms was favourable, and the clinical course was benign even in the
36% of patients who developed SS. No cases of lymphoma were observed.
(Ann Rheum Dis 1999;58:423-427)
| |
Introduction |
|---|
|
|
|---|
Sjögren's syndrome (SS) is a chronic autoimmune exocrinopathy characterised by dryness of eyes (keratoconjunctivitis sicca) and mouth (xerostomia) as well as recurrent parotid or submandibular gland swellings. The clinical course of SS has been regarded as chronic, mild and stable. However, apart from the effects on the lacrimal and salivary glands, various extraglandular manifestations may develop. Also, an increased risk of lymphoproliferative diseases, especially of non-Hodgkin's lymphoma, has been related to SS.1
Scant attention has been paid to the prognosis and progression of mild, smouldering diseases and sicca symptoms. Forstot et al made a study of 45 patients with keratoconjunctivitis sicca with respect to oral and serological findings and observed SS in eight (17%).2 In a long term follow up study of 106 SS patients a subgroup of patients with isolated keratoconjunctivitis sicca was also described.3 None of the patients with isolated keratoconjunctivitis sicca developed lymphoproliferative disease.
Our study was specifically designed to evaluate the prognosis of SS in the mildest forms of its clinical spectrum and to obtain further information on the natural history of primary SS (pSS). The main purpose was to identify the most useful clinical and immunological indicators of the subsequent development of SS in patients with early onset sicca symptoms.
| |
Methods |
|---|
|
|
|---|
SELECTION OF SUBJECTS WITH SICCA SYMPTOMS FOR RE-EVALUATION
The charts of 259 subjects with sicca symptoms initially examined
in the Department of Internal Medicine, Section of Rheumatology, in
Tampere University Hospital during the years 1977 to 1986 were reviewed
by one of the authors (MP). Californian criteria4 with the
modifications that salivary flow rate measurements were not performed
and the histological findings were graded according to the
Chisholm-Mason scale5 grades 3 and 4 regarded as
diagnostic, were applied in the diagnosis of SS. One hundred and nine
patients with sicca symptoms fulfilling two or less of the criteria
were included in the study. Of these, 14 subjects had died; the causes of death being cardiovascular in seven, malignancy in five, hepatic cirrhosis in one, and accident in one patient. The remaining 95 subjects were invited for re-evaluation. A total of 87 subjects (92%
of those invited) attended the study. They comprised 72 women and 15 men with a median age of 60 years (range, 28-80 ) and a median follow
up time of 11 years (range, 8-17).
METHODS OF RE-EVALUATION
The clinical examination included a thorough interview covering
family history, previous diseases, previous and concurrent medications,
drug allergies, duration of sicca symptoms, first manifestation of the
disease, existence of recurrent parotid or submandibular gland
swellings, and present sicca symptoms of the eyes and mouth. The
existence of xerostomia was defined as subjective troublesome daily
feeling of dry mouth for more than three months. Special emphasis was
focused on possible extraglandular symptoms (musculoskeletal,
dermatological, renal, neurological, vascular, respiratory,
gastrointestinal, endocrine and lymphoproliferative symptoms).
Rheumatoid factor (RF) was determined by Waaler-Rose agglutination test
(at baseline) and by laser nephelometry (at follow up). Antinuclear
antibodies (ANA) were determined by indirect immunofluorescence on
multiblock cryostat sections, comprising rat liver and mouse kidney,
heart and stomach (at baseline) and using Hep-2 cells (at follow up).
Antibodies to extractable nuclear antigens (ENA), including
anti-ribonucleoprotein (RNP), anti-Sm, anti-SS-A, anti-SS-B and
anti-Scl 70 antibodies, as well as antibodies to native DNA (QUANTA
Lite ENA 5 ELISA and QUANTA Lite ds DNA, INOVA Diagnostics Inc, San
Diego, CA), were measured by enzyme immunoassay. Anti-salivary gland
antibodies were analysed by indirect immunofluorescence (Monkey
Salivary Gland Slide, INOVA Diagnostics Inc). Serum concentrations of
immunoglobulin IgA, IgG and IgM, as well as serum complement levels (C3
and C4), were measured by laser nephelometry. Serum
2m
was determined by radioimmunoassay (Pharmacia beta-2-micro RIA kit,
Pharmacia Diagnostics Uppsala, Sweden, the reference values being
1.0
2.5 mg/l).
Ophthalmological examination was performed at baseline and at follow up
(the latter by one senior ophthalmologist, HU). Tear fluid secretion
9 mm/5 min in Schirmer's test and break up time <10 s were defined
as abnormal test results. Rose-Bengal test was performed by the
application of 1% solution of Rose-Bengal dye using a glass applicator
and by evaluating abnormal staining at the interpalpebral area of the
cornea and conjunctiva using a slit lamp. Keratoconjunctivitis sicca
was established if diagnostic criteria (decreased Schirmer test result
and abnormal staining in Rose-Bengal test) were met in at least one eye.
Labial salivary gland biopsy was performed at baseline in 73 of the 87 patients and the histological findings were graded according to the Chisholm-Mason scale (grades 0-4).5 At follow up labial biopsy was repeated for those patients who had grade 0-2 histological findings initially and who gave their informed consent. A thorough otorhinolaryngological examination was made and follow up labial salivary gland biopsy samples through lower lip mucosal incision were taken by a senior otorhinolaryngologist (JP). The histological evaluation was made blind to the clinical data by an experienced pathologist (HH). The study design was approved by the Ethical Committee of Tampere University Hospital.
STATISTICAL ANALYSIS
To evaluate differences between the patient groups, Student's
t test and
2 test with
Yates's correction were used for continuous and dichotomous variables,
respectively. Logistic regression analysis was applied to evaluate the
independent effect of different laboratory findings on the prognosis of
the disease.
| |
Results |
|---|
|
|
|---|
DEMOGRAPHIC CHARACTERISTICS OF THE PATIENT GROUPS AND THE SICCA
AND XEROSTOMIA SYMPTOMS
At follow up 31 patients (26 women, 5 men) out of 87 (36%)
fulfilled modified Californian criteria for possible (22 patients) or
definite (9 patients) SS (referred to as the SS group). Twenty nine of
these patients had primary and two had secondary SS to either
rheumatoid arthritis or mixed connective tissue disease (MCTD). In the
patient group not fulfilling the criteria for SS (referred to as the
sicca group) two patients fulfilled the criteria for rheumatoid
arthritis and one had undifferentiated connective tissue disease (UCTD)
at follow up. Furthermore, three patients in the sicca group had
features of a seronegative spondylarthropathy and two of a
non-specified oligoarthritis. The sicca group comprised 56 patients (46 women, 10 men).
Patients in the SS group were significantly older than those in the
sicca group (mean (SD) 63 (8) v 55 (13)
years at follow up, p
0.005). The duration of xerostomia was
significantly longer in the SS group compared with the sicca group (13 (7) v 10 (7) years, p
0.05); but the
difference in the duration of sicca symptoms in the eyes between the SS
and sicca groups (13 (10) and 11 (7) years, respectively) was not
statistically significant.
Sicca symptoms of the eyes did not occur as frequently at baseline in
the SS group (61%) as in the sicca group (84%). Both xerostomia and a
history of either parotid or submandibular gland swelling were found at
baseline more frequently in the SS group (77% and 32%, respectively)
compared with the sicca group (63% and 20%, respectively). Neither of
the differences was statistically significant. There were no
statistically significant differences in previous or concurrent use of
diuretics,
blockers, psychiatric medication, tear and salivary
substituents, corticosteroids or disease modifying antirheumatic drugs
between the patient groups.
OPHTHALMOLOGICAL FINDINGS
Table 1 describes the ophthalmological findings. At baseline 53%
of the patients in the SS group and 57% of those in the sicca group
had abnormal results in Schirmer's test. Abnormal staining in
Rose-Bengal test was constituted at baseline in 56% and 40% of the
patients in SS and sicca groups, respectively. The criteria of
keratoconjunctivitis sicca were fulfilled on the whole in 32% of the
patients in both groups at baseline.
|
LABIAL SALIVARY GLAND BIOPSY SPECIMENS
New labial salivary gland biopsy specimens were taken from 55 patients, and 50 of these were representative (containing more than
four minor salivary glands/4 mm2). The biopsy was not
performed in 11 patients with grade 3 or 4 findings already at
baseline. Twenty one were reluctant to undergo re-biopsy. Evaluable
baseline and second labial salivary gland biopsy specimens were
available from 42 patients. Of the 42 labial salivary gland re-biopsies
of patients with grade 0-2 findings at baseline, progression to grades
3-4 was observed in 21 (50%) at follow up (table 2); of those,
altogether 12 specimens progressed from grade 0-2 up to grade 4
that
is, to a finding of two or more lymphocytic focuses. The histological
progression extended to at least two grades in 17 (40%) of these
specimens
two grades in nine biopsy specimens, three grades in seven
and four grades in one biopsy specimen
as compared with the baseline
specimens.
|
EXTRAGLANDULAR MANIFESTATIONS
At follow up there were no significant differences between the
patient groups in the frequency of arthralgias or arthritis. Erosive
arthritis was detected in only one patient in the SS group, and in two
patients in the sicca group; all the patients with erosive arthritis
had also rheumatoid arthritis. The frequencies of Raynaud's
phenomenon, peripheral or central nervous system symptoms between the
patient groups did not differ. Myositis was not found. Pleuritis had
occurred in six (19%) of the patients in the SS group and in two (4%)
subjects in the sicca group but its relation to SS can retrospectively
not be assured. Pericarditis had appeared in no patient in the SS group
and in two (4%) patients in the sicca group. In the SS group two
patients (6%) had pulmonary fibrosis and one patient (3%) had
lymphocytic interstitial pneumonitis. Furthermore, one patient (3%) in
the SS group had a biopsy confirmed interstitial nephritis. In the
sicca group four patients had developed breast cancer, but in the SS
group no malignancies occurred.
STANDARD LABORATORY TESTS
There were no significant differences between the patient groups
in blood haemoglobin concentration, serum white blood cell count, serum
platelet count, serum C reactive protein, serum creatinine, serum
alanine aminotransferase or serum alkaline phosphatase at baseline or
at follow up. The patients in the SS group had significantly higher
erythrocyte sedimentation rate (ESR) at baseline compared with the
sicca group (mean (SD) 29 (25) v 20 (19),
p
0.05).
IMMUNOSEROLOGICAL TESTS
There were no differences between the patient groups in the
frequency of positive results in the Waaler-Rose test at baseline (table 3). The SS group had ANA more frequently at baseline than the
sicca group (26% v 3%, p
0.01). ENA
antibody determinations were available comprehensively only at follow
up; the occurrence of SS-A and SS-B antibodies was significantly higher
among the SS patients than in the sicca group (40%
v 5%, p
0.001 and 33% v 4%, p
0.001, respectively) (table 3).
There were no significant differences in the levels of serum complement
components (C3 and C4) between the patient groups at baseline. The
concentrations of serum
globulin and serum IgG as well as the level
of serum
2m were significantly higher in the SS group
than in the sicca group at baseline (table 3).
|
LOGISTIC REGRESSION ANALYSIS
As several of the clinical and laboratory findings were likely to
be intercorrelated, a logistic regression analysis was performed to
assess their independent impact on disease outcome. The effect of ESR
was found to be dependent on age, but the significance of the other
parameters tested (ANA positivity, serum
globulin, serum IgG, serum
2m) was found to prevail irrespective of the effect of
age as predictors of later development of SS (table 4). Age, ESR, ANA
positivity, serum
globulin and IgG concentrations as well as serum
2m levels were also tested all together in a logistic
regression model in a backward stepwise manner to eliminate intercorrelation of these parameters. Age, ANA positivity and serum
2m were found to be independent predictive factors for the development of SS in subjects with sicca symptoms (table
4).
|
| |
Discussion |
|---|
|
|
|---|
Our main result was, that 31 of 87 subjects (36%) with either
complaints of dryness of eyes or mouth, or both, developed SS after a
median follow up time of 11 years. Factors that could predict the
development of clinical SS were: higher age, positive antinuclear
antibodies, increased concentrations of serum
globulin and serum
IgG as well as a high concentration of serum
2m.
Furthermore, our results showed that there was a significant
progression in the histological findings in labial salivary gland
specimens in the course of time. No cases of lymphoma were found.
The proportion of the patients who finally developed clinically evident SS (approximately one third of the group) seems to be fairly small considering the length of the follow up (median 11 years). This implies that the development of SS is probably a particularly slow process. We had modified the Californian criteria,4 and regarded as diagnostic histological findings those with at least one lymphocytic focus. If we had adhered strictly to the Californian criteria necessitating more than one lymphocytic focus to be found to establish the diagnosis, the proportion of patients having developed SS would naturally have been even smaller. In previous studies, even lower frequencies of SS among patients with sicca or xerostomia symptoms have been noted. In an earlier prospective study among 45 patients with keratoconjunctivitis sicca, xerostomia was observed in 15 patients (33%) but complete SS in only eight (17%).2 Markusse et al6 found that only 20% of patients (10 of 50) with eventual SS were diagnosed at their first rheumatological visit, and the diagnostic delay was on the average three years. In a retrospective study of 47 patients with pSS, it was noted that an average of eight years had elapsed before the diagnosis was made.7 In a prospective study on sicca symptoms of six patients with primary and nine with secondary SS it was shown that both subjective sicca symptoms and objective findings of glandular involvement progress, although very slowly, and that three patients with subclinical disease developed clinical SS in six years.8 In another study, none of 56 patients with isolated keratoconjunctivitis sicca was reported to have developed SS at follow up 10-12 years after the initial diagnosis.3 In that study, however, the follow up assessment did not include a second labial salivary gland biopsy.3
It might be argued that had we applied the EEC criteria9 instead of the Californian4 in diagnosing SS, some of our patients with sicca symptoms would have fulfilled the criteria already at baseline. However, in that case these subjects would have been excluded from the study, and correspondingly the percentual proportion of the patients fulfilling the diagnostic criteria at follow up would thus not necessarily differ from the current results.
In our study there was no progression in the ophthalmological findings in the sicca group during the follow up. This is in accordance with results of an earlier study10 where the course of keratoconjunctivitis sicca was evaluated. It was found that the Schirmer test results remained unchanged and the average ocular findings evaluated by break up time and Rose-Bengal tests improved during the mean follow up period of 53 months.10 Also in the study by Kruize et al,3 the proportion of patients with keratoconjunctivitis sicca having inflammatory reaction of eyes, was lower at follow up than at baseline. In our study, however, progression of the ocular findings was observed in the SS group (table 2).
There was a significant progression of histological findings in this study. Serial assessments of histological findings have been described in patients with SS.11 12 In these studies also, the lesions were mainly progressive with time. Leroy et al11 report that even eight of the nine initially negative analyses were positive on the second sample. Jonsson et al12 observed morphological progression of sialadenitis in 14 of 21 patients (67%) with primary SS, and in 14 of 18 patients (78%) with secondary SS after a mean (SD) follow up time of 39 (20) months.
Martinez-Lavin et al13 found that identification of SS-A and SS-B antibodies helped for establishing the findings of SS in patients in whom the diagnosis had not been considered at the initial examination. The prognostic value of SS-A antibodies has been confirmed by others.14 Otherwise, no predictive factors for SS development have previously been suggested. In a large follow up material of Kruize et al3 involving both SS patients (31 primary and 19 secondary) and keratoconjunctivitis sicca patients (56) it was sought to find laboratory factors predictive of the development of extraglandular symptoms of SS, but no such factors were found.
In our study higher age at onset, ANA positivity and high serum serum
2m levels attained statistical significance and proved to be independent predictive factors for the later development of SS
also in a logistic regression model. Previously, high serum
2m values have been reported especially in SS patients
with lymphoproliferative complications or renal
involvement.15 It is noteworthy that in our study SS-A and
SS-B antibodies were not included in the analysis of predictive factors
because of the fact that the earliest baseline examinations were
performed already in the 1970s when SS-A and SS-B antibody
determinations were not available in clinical practice.
No patients with lymphoma were recorded in our study. The increased risk of lymphoma in SS has previously been described in several studies.1 3 16 17 Our study was focused on a population in which the diagnosis of SS was not yet established in the first evaluation, and thus the observation period was probably shorter than in populations where the diagnosis of SS is already apparent. In a recent follow up study (median 34 months) of 100 patients with primary SS, lymphoma was found in excess (three patients).18
In conclusion, our results suggest that higher age, increased
concentrations of serum
2m, ANA positivity and, to a
lesser extent, high concentrations of serum
globulin and serum IgG, might be useful indicators for the subsequent development of SS in
patients with sicca symptoms. There was a significant progression in
the histological findings in labial salivary gland biopsies over time,
and it might thus be justified to take a new labial salivary gland
biopsy specimen after some years to confirm the diagnosis of SS in
cases where the first specimen has proved negative in patients with
persisting symptoms and indicators suggestive of SS. In our study the
prognosis of patients with sicca symptoms was favourable and the
clinical course was benign even in those patients who developed SS. No
cases of lymphoma were observed.
| |
Acknowledgments |
|---|
We wish to thank Anna-Maija Koivisto, MSc, for her help in the statistical analysis.
| |
Footnotes |
|---|
Funding: this study was supported by grants from the Medical Research Fund of Tampere University Hospital and the Tampere Rheumatism Association.
| |
References |
|---|
|
|
|---|
| 1. | Talal N, Bunim JJ. Development of malignant lymphoma in the course of Sjögren's syndrome. Am J Med 1964;36:529-540[Medline]. |
| 2. | Forstot JZ, Forstot SL, Greer RO, Tan EM. The incidence of Sjögren's sicca complex in a population of patients with keratoconjunctivitis sicca. Arthritis Rheum 1982;25:156-160[Medline]. |
| 3. | Kruize AA, Hené RJ, van der Heide A, Bodeutsch C, Wilde PCM, van Bijsterveld OP, et al. Long-term follow-up of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:297-303[Medline]. |
| 4. | Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum 1986;29:577-585[Medline]. |
| 5. |
Chisholm DM,
Mason DK. Labial salivary gland biopsy in Sjögren's syndrome.
J Clin Pathol
1968;21:656-660 |
| 6. | Markusse HM, Oudkerk M, Vroom TM, Breedveld FC. Primary Sjögren's syndrome: clinical spectrum and mode of presentation based on an analysis of 50 patients selected from a department of rheumatology. Neth J Med 1992;40:125-134[Medline]. |
| 7. | Pavlidis A, Karsh J, Moutsopoulos H. The clinical picture of primary Sjögren's syndrome: a retrospective atudy. J Rheumatol 1982;9:685-690[Medline]. |
| 8. | Ichikawa Y, Takaya M, Uchiyama M, Shimizu H, Tokunaga M, Saitoh H, et al. Prospective studies on the progress of sicca symptoms in Sjögren's syndrome: subclinical disease develops into the clinical syndrome. Tokai J Exp Clin Med 1988;13:85-90[Medline]. |
| 9. | Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome: results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-347[Medline]. |
| 10. | Kriegsbaum N, von Linstow M, Oxholm P, Prause JU. Keratoconjunctivitis sicca in patients with primary Sjögren's syndrome. A longitudinal study of ocular parameters. Acta Ophthalmol 1988;66:481-484. |
| 11. |
Leroy JP,
Pennec YL,
Soulier C,
Berthelot JM,
Letoux G,
Youinou P. Follow up study of labial salivary gland lesions in primary Sjögren's syndrome.
Ann Rheum Dis
1992;51:777-780 |
| 12. |
Jonsson R,
Kroneld U,
Bäckman K,
Magnusson B,
Tarkowski A. Progression of sialadenitis in Sjögren's syndrome.
Br J Rheumatol
1993;32:578-581 |
| 13. | Martinez-Lavin M, Vaughan JH, Tan EM. Autoantibodies and the spectrum of Sjögren's syndrome. Ann Intern Med 1979;91:185-190. |
| 14. | Simmons-O'Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, et al. One hundred anti-Ro (SS-A) antibody positive patients: A 10 year follow-up. Medicine (Baltimore) 1995;74:109-130[Medline]. |
| 15. | Michalsky JP, Daniels TE, Talal N, Grey HM. Beta-2-microglobulin and lymphocytic infiltration in Sjögren's syndrome. N Engl J Med 1975;293:1228-1231[Abstract]. |
| 16. | Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RB, Budman DR, et al. Increased risk of lymphoma in Sjögren's syndrome. Ann Intern Med 1978;89:888-892. |
| 17. | Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren's syndrome (SS) and malignant lymphoma. Scand J Rheumatol 1995;24:342-345[Medline]. |
| 18. |
Kelly CA,
Foster H,
Pal B,
Gardiner P,
Malcolm AJ,
Charles P,
et al. Primary Sjögren's syndrome in North East England - a longitudinal study.
Br J Rheumatol
1991;30:437-442 |
© 1999 by Annals of the Rheumatic Diseases
This article has been cited by other articles:
-
Pertovaara, M., Kahonen, M., Juonala, M., Laitinen, T., Taittonen, L., Lehtimaki, T., Viikari, J. S. A., Raitakari, O. T., Hurme, M.
(2009). Autoimmunity and atherosclerosis: the presence of antinuclear antibodies is associated with decreased carotid elasticity in young women. The Cardiovascular Risk in Young Finns Study. Rheumatology (Oxford)
48: 1553-1556
[Abstract] [Full Text] -
PERTOVAARA, M., JYLHAVA, J., UUSITALO, H., PUKANDER, J., HELIN, H., HURME, M.
(2009). Serum Amyloid A and C-Reactive Protein Concentrations Are Differently Associated with Markers of Autoimmunity in Patients with Primary Sjogren's Syndrome. The Journal of Rheumatology
36: 2487-2490
[Abstract] [Full Text] -
Fox, P. C., Bowman, S. J., Segal, B., Vivino, F. B., Murukutla, N., Choueiri, K., Ogale, S., McLean, L.
(2008). Oral involvement in primary Sjogren syndrome. Journal of the American Dental Association
139: 1592-1601
[Abstract] [Full Text] -
Lodde, B. M., Sankar, V., Kok, M. R., Leakan, R. A., Tak, P. P., Pillemer, S. R.
(2006). Serum lipid levels in Sjogren's syndrome. Rheumatology (Oxford)
45: 481-484
[Abstract] [Full Text] -
van Woerkom, J M, Kruize, A A, Wenting - van Wijk, M J G, Knol, E, Bihari, I C, Jacobs, J W G, Bijlsma, J W J, Lafeber, F P J G, van Roon, J A G
(2005). Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared with non-Sjogren's sicca syndrome. Ann Rheum Dis
64: 1474-1479
[Abstract] [Full Text] -
Ramos-Casals, M, Tzioufas, A G, Font, J
(2005). Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis
64: 347-354
[Abstract] [Full Text] -
Sanchez-Guerrero, J., Aguirre-Garcia, E., Perez-Dosal, M. R., Kraus, A., Cardiel, M. H., Soto-Rojas, A. E.
(2002). The wafer test: a semi-quantitative test to screen for xerostomia. Rheumatology (Oxford)
41: 381-389
[Abstract] [Full Text] -
Pertovaara, M, Pukkala, E, Laippala, P, Miettinen, A, Pasternack, A
(2001). A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis
60: 467-472
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
